polatuzumab vedotin,rituximab,cyclophosphamide,doxorubicin,vincristine,prednisolone 
roche
['pola', 'dlbcl', 'lymsm']
risk stratification of dlbcl with mved2 score (tmtv + ecog + dmax + adipose density) #17icml
- 273 pts from remarc
- mved2 predicts pfs &amp; os with rchop
- mved2 better than other indices for pfs &amp; os
curious if this is also prognostic with pola-r-chp. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈